VVT Medical recently announced the signing of a strategic distribution agreement with Methapharm, a specialty pharmaceutical company.
According to a press release, this collaboration marks a pivotal moment in the realm of varicose vein treatment, leveraging the strengths of both entities for the marketing of VVT Medical’s ScleroSafe platform in the USA.
The ScleroSafe platform received its 510(k) clearance from the US Food and Drug Administration (FDA) in June 2023, which laid the foundation for this strategic partnership. ScleroSafe is a novel medical device that utilises a dual syringe technique, VVT Medical notes.
The press release continues that Methapharm is uniquely positioned to spearhead the distribution of ScleroSafe, due to its extensive expertise in varicose veins and its relationships with key stakeholders and physicians in the USA.
The collaboration is further fortified by the strong synergy between the two companies, the release adds, sharing application in the same procedure for efficient, non-thermal, non-tumescent (NT-NT) treatment and management of varicosities in superficial veins.
Erez Tetro, CEO of VVT Medical, stated: “ScleroSafe holds the promise of transforming varicose vein treatment, providing patients with a safe, effective, and straightforward option.” He emphasised the collaboration with Methapharm, saying: “We have strong confidence in the positive influence our product can bring to the lives of many throughout the USA, and we consider Methapharm as the ideal collaborator to realise this vision.”
Craig Baxter, CEO of Methapharm stated: “We at Methapharm are very excited to form this strategic relationship with VVT Medical, and we look forward to adding ScleroSafe to our offerings. We believe it will contribute significantly to our efforts to continually offer the best possible patient care.”
